意大利直接口服抗凝剂（DOACs）应用前后心房颤动患者的抗栓治疗模式：REPAIR研究
Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study.
作者信息
Esposti Luca D, Briere Jean-Baptiste, Bowrin Kevin, Diego Sangiorgi, Perrone Valentina, Pasquale Giuseppe Di
机构信息
CliCon Srl, Health Economics and Outcomes Research, Ravenna, Italy.
Bayer AG, Berlin, Germany.
出版信息
Future Cardiol. 2019 Mar;15(2):109-118. doi: 10.2217/fca-2018-0009. Epub 2019 Jan 21.
AIM
To evaluate antithrombotic treatment patterns in patients in Italy with nonvalvular atrial fibrillation (NVAF) before and after direct oral anticoagulants (DOACs) were approved.
METHODS
This analysis included patients with a discharge diagnosis of NVAF in 2010 and 2014, which constituted the pre- and post-DOACs populations, respectively.
RESULTS
Approximately 90% of patients were eligible for oral anticoagulant (OAC) therapy. Overall use of OACs increased from 38% in 2010 to 45% in 2014; use of antiplatelet therapy decreased from 36 to 25%. Approximately 14% of eligible patients remained untreated.
CONCLUSION
Although an improvement in OAC prescription was observed post-DOACs launch, treatment patterns in Italy suggest that a proportion of patients with NVAF are still undertreated or do not receive appropriate therapy.
目的
评估在直接口服抗凝剂（DOACs）获批前后，意大利非瓣膜性心房颤动（NVAF）患者的抗血栓治疗模式。
方法
本分析纳入了2010年和2014年出院诊断为NVAF的患者，分别构成DOACs获批前和获批后的人群。
结果
约90%的患者符合口服抗凝剂（OAC）治疗条件。OACs的总体使用率从2010年的38%增至2014年的45%；抗血小板治疗的使用率从36%降至25%。约14%符合条件的患者仍未接受治疗。
结论
尽管在DOACs推出后观察到OAC处方有所改善，但意大利的治疗模式表明，一部分NVAF患者仍未得到充分治疗或未接受适当治疗。
Zotero 插件